12022



Poster Session

The predictive role of mammographic breast calcifications in cardiovascular disease among women undergoing breast cancer screening: Insights from a retrospective database analysis of breast cancer screening.

Usman Ali Akbar, Umer Rizwan, Rida Hussain, Ahmed Muaaz Umer, Andrea Dwiggins, Sabir Hussain, Michael Cheshire; West Virginia University Camden Clark Medical Center, Parkersburg, WV; Camden Clark Medical Center, Parkersburg, WV; West Virginia School of Osteopathic Medicine, Lewisburg, WV; WVU Camden Clark Medical Center, Parkersburg, WV

Background: Cancer screenings, particularly mammography, are crucial in early detection and management of breast cancer, the most common cancer among women worldwide. Despite advances, disparities persist in cancer outcomes and cardiovascular health, highlighting the need for an integrative approach to care. Methods: We conducted a retrospective cohort analysis of 22,118 female patients over 40 years of age diagnosed with breast arterial calcification (BAC) on mammography using the TriNetX database. Each patient with BAC was matched to a control based on age, lab values, socioeconomic class, and co-morbidities. None had ASCVD events before screening. Outcomes included acute myocardial infarction, heart failure, cardiomyopathy, and thromboembolic events. Results: Comparing cohorts with and without BAC, we found no significant difference in all-cause mortality (OR: 1.003, P=0.960). However, BAC was associated with increased risks of acute myocardial infarction (OR: 1.281, P=0.003), heart failure (OR: 1.106, P=0.021), cardiomyopathy (OR: 1.437, P<0.001), and DVT/PE (OR: 1.178, P=0.006), particularly DVT (OR: 1.243, P=0.003). Ischemic stroke, CVD, and other cardiovascular conditions showed no significant risk differences, highlighting BAC's predictive value for specific cardiovascular outcomes (Table). Conclusions: Our findings affirm BAC on mammography as a significant predictor of specific cardiovascular conditions, such as acute myocardial infarction and heart failure, highlighting its utility in cardiovascular risk stratification. Research Sponsor: None.

| Outcome | Risk Difference (%) | OR (95% CI) | P Value | 95% CI of OR | Event Rates (Calcification Cohort) | Event Rates (No Calcificatior Cohort) |
|-----------------------------------|------------------------|---------------------|---------|-----------------|--|---|
| All-Cause Mortality | 0.0 | 1.003 (0.908-1.106) | 0.960 | (0.908-1.106) | 823/22084 | 821/22084 |
| Acute Myocardial Infarction | 0.3 | 1.281 (1.085-1.511) | 0.003 | (1.085-1.511) | 323/22084 | 253/22084 |
| Heart Failure | 0.5 | 1.106 (1.015-1.206) | 0.021 | (1.015-1.206) | 1148/22084 | 1043/22084 |
| Ischemic Stroke | -0.0 | 0.985 (0.697-1.391) | 0.930 | (0.697-1.391) | 64/22084 | 65/22084 |
| DVT/PE | 0.4 | 1.178 (1.048-1.324) | 0.006 | (1.048-1.324) | 631/22084 | 538/22084 |
| Cardiac Arrest | 0.0 | 1.133 (0.817-1.571) | 0.454 | (0.817-1.571) | 77/22084 | 68/22084 |
| Peripheral Vascular Disease | 0.3 | 1.092 (0.981-1.215) | 0.107 | (0.981-1.215) | 722/22084 | 663/22084 |
| CABG/PCI | 0.2 | 1.197 (0.996-1.440) | 0.055 | (0.996-1.440) | 251/22084 | 210/22084 |

Mycoardial Infarction, CABG: Coronary Artery Bypass Grafting, PCI: Percutaneous Coronary Intervention, ASCVD: Atherosclerotic Cardiovascular Disease.